Anavex Life Sciences Corp logo

Anavex Life Sciences Corp

FRA:12X1 (USA)  
€ 4.68 (+7.51%) Mar 28
At Loss
P/B:
3.08
Market Cap:
€ 385.80M ($ 416.19M)
Enterprise V:
€ 252.84M ($ 271.72M)
Volume:
-
Avg Vol (2M):
2.46K
Also Trade In:

Business Description

Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.92
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 60.44
9-Day RSI 53.4
14-Day RSI 50.03
6-1 Month Momentum % -25.37
12-1 Month Momentum % -38.13

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.85
Quick Ratio 11.85
Cash Ratio 11.51

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.8
Shareholder Yield % -6.68
Name Current Vs Industry Vs History
ROE % -30.63
ROA % -28.1
ROIC % -2251.56
ROCE % -33.31

Financials (Next Earnings Date:2024-05-09 Est.)

FRA:12X1's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Anavex Life Sciences Corp Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.511
Beta 1.48
Volatility % 66.63
14-Day RSI 50.03
14-Day ATR (€) 0.239116
20-Day SMA (€) 4.58075
12-1 Month Momentum % -38.13
52-Week Range (€) 4.062 - 9.322
Shares Outstanding (Mil) 82.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Anavex Life Sciences Corp Filings

Filing Date Document Date Form
No Filing Data

Anavex Life Sciences Corp Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Anavex Life Sciences Corp Frequently Asked Questions

What is Anavex Life Sciences Corp(FRA:12X1)'s stock price today?
The current price of FRA:12X1 is €4.68. The 52 week high of FRA:12X1 is €9.32 and 52 week low is €4.06.
When is next earnings date of Anavex Life Sciences Corp(FRA:12X1)?
The next earnings date of Anavex Life Sciences Corp(FRA:12X1) is 2024-05-09 Est..
Does Anavex Life Sciences Corp(FRA:12X1) pay dividends? If so, how much?
Anavex Life Sciences Corp(FRA:12X1) does not pay dividend.

Press Release

Subject Date
No Press Release